Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in RRMM with Sub-Optimal Response to Idecabtagene Vicleucel
NCT06523621Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Primary endpoint: Depth of Response at 5 months. Started Feb 2025; status: active, not recruiting.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06523621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523621.